SE446130B - Komposition for bestemning av human beta?712-mikroglobulin, forfarande for framstellning derav samt sett att bestemma human beta?712-mikroglobulin - Google Patents
Komposition for bestemning av human beta?712-mikroglobulin, forfarande for framstellning derav samt sett att bestemma human beta?712-mikroglobulinInfo
- Publication number
- SE446130B SE446130B SE7907118A SE7907118A SE446130B SE 446130 B SE446130 B SE 446130B SE 7907118 A SE7907118 A SE 7907118A SE 7907118 A SE7907118 A SE 7907118A SE 446130 B SE446130 B SE 446130B
- Authority
- SE
- Sweden
- Prior art keywords
- human
- microglobulin
- latex
- particles
- styrene
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 41
- 239000000203 mixture Substances 0.000 title claims description 29
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 title claims 4
- 102000055647 human CSF2RB Human genes 0.000 title claims 4
- 239000004816 latex Substances 0.000 claims description 55
- 229920000126 latex Polymers 0.000 claims description 55
- 239000002245 particle Substances 0.000 claims description 39
- 210000002966 serum Anatomy 0.000 claims description 20
- 210000002700 urine Anatomy 0.000 claims description 19
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 6
- 229920001059 synthetic polymer Polymers 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims 1
- 101000738546 Homo sapiens Protein PTHB1 Proteins 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 102000051324 human BBS9 Human genes 0.000 claims 1
- 238000003475 lamination Methods 0.000 claims 1
- 239000011785 micronutrient Substances 0.000 claims 1
- 235000013369 micronutrients Nutrition 0.000 claims 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 10
- 230000004520 agglutination Effects 0.000 description 10
- 102000047279 human B2M Human genes 0.000 description 10
- 101000986079 Homo sapiens HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012475 sodium chloride buffer Substances 0.000 description 3
- ZFEKVFJKFDZSHE-UHFFFAOYSA-M sodium;2-aminoacetic acid;chloride Chemical compound [Na+].[Cl-].NCC(O)=O ZFEKVFJKFDZSHE-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- SBYMUDUGTIKLCR-UHFFFAOYSA-N 2-chloroethenylbenzene Chemical compound ClC=CC1=CC=CC=C1 SBYMUDUGTIKLCR-UHFFFAOYSA-N 0.000 description 1
- ZSQWQTABLXAFEZ-UHFFFAOYSA-N 2-phenylbut-3-enoic acid Chemical compound OC(=O)C(C=C)C1=CC=CC=C1 ZSQWQTABLXAFEZ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WRVRNZNDLRUXSW-UHFFFAOYSA-N acetic acid;prop-2-enoic acid Chemical compound CC(O)=O.OC(=O)C=C WRVRNZNDLRUXSW-UHFFFAOYSA-N 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013208 measuring procedure Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10389078A JPS5530652A (en) | 1978-08-28 | 1978-08-28 | Latex sensitive to antibody of human beta2-microglobulin for quantitizing human beta2-microglobulin and its composite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7907118L SE7907118L (sv) | 1980-02-29 |
| SE446130B true SE446130B (sv) | 1986-08-11 |
Family
ID=14366013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7907118A SE446130B (sv) | 1978-08-28 | 1979-08-27 | Komposition for bestemning av human beta?712-mikroglobulin, forfarande for framstellning derav samt sett att bestemma human beta?712-mikroglobulin |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5530652A (de) |
| CH (1) | CH645727A5 (de) |
| DE (1) | DE2934756C2 (de) |
| FR (1) | FR2435039A1 (de) |
| GB (1) | GB2030294B (de) |
| SE (1) | SE446130B (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59224565A (ja) * | 1983-04-28 | 1984-12-17 | Morinaga Milk Ind Co Ltd | 抗原検出用試薬 |
| US4575486A (en) * | 1983-10-26 | 1986-03-11 | International Remote Imaging Systems, Inc. | Process for differentiating the origin of particles in urine |
| EP0236509B1 (de) * | 1985-09-19 | 1993-02-10 | Toray Industries, Inc. | Kolonne zum entfernen von beta-2-mikroglobulin |
| US5175113A (en) * | 1986-01-16 | 1992-12-29 | Novo Nordisk A/S | Modified β2 -microglobulin |
| DK160944C (da) * | 1986-01-16 | 1991-10-21 | Novo Industri As | Modificerede beta2-mikroglobuliner og farmaceutiske praeparater indeholdende disse |
| EP0247592B1 (de) * | 1986-05-30 | 1992-03-04 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Sorbentmittel für beta 2-Mikroglobulin und Immunoglobulin L-Kette |
| NL8602915A (nl) * | 1986-11-17 | 1988-06-16 | Innogenetics Nv | Werkwijze en diagnostisch middel voor het diagnostiseren en/of prospectief volgen van letsel ter hoogte van de pulmonaire microcirculatie. |
| US20020164818A1 (en) | 1995-05-23 | 2002-11-07 | Gruber Karl F. | Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids |
| CN108872590A (zh) * | 2018-06-29 | 2018-11-23 | 宁波海壹生物科技有限公司 | 可同时检测血清和尿液样本中β2-微球蛋白的试剂盒 |
| CN109975550A (zh) * | 2018-12-29 | 2019-07-05 | 宁波普瑞柏生物技术股份有限公司 | 消除β2-微球蛋白检测中钩状效应的方法和试剂盒 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3088875A (en) * | 1959-10-27 | 1963-05-07 | Hyland Lab | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron |
| NL125235C (de) * | 1965-04-15 | |||
| GB1384399A (en) * | 1971-02-01 | 1975-02-19 | Hoffmann La Roche | Automated method of obtaining serological data |
-
1978
- 1978-08-28 JP JP10389078A patent/JPS5530652A/ja active Pending
-
1979
- 1979-08-27 SE SE7907118A patent/SE446130B/sv not_active IP Right Cessation
- 1979-08-27 CH CH776879A patent/CH645727A5/de not_active IP Right Cessation
- 1979-08-28 DE DE19792934756 patent/DE2934756C2/de not_active Expired
- 1979-08-28 GB GB7929797A patent/GB2030294B/en not_active Expired
- 1979-08-28 FR FR7921528A patent/FR2435039A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5530652A (en) | 1980-03-04 |
| GB2030294A (en) | 1980-04-02 |
| SE7907118L (sv) | 1980-02-29 |
| FR2435039A1 (fr) | 1980-03-28 |
| DE2934756C2 (de) | 1984-11-08 |
| CH645727A5 (de) | 1984-10-15 |
| DE2934756A1 (de) | 1980-03-13 |
| GB2030294B (en) | 1983-03-02 |
| FR2435039B1 (de) | 1984-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1149277A (en) | Process for determining immuno-complexes | |
| Hay et al. | Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q | |
| Heimer et al. | Globulins resembling rheumatoid factor in serum of the aged | |
| Masouredis | RELATIONSHIP BETWEEN Rh 0 (D) GENOTYPE AND QUANTITY OF I 131 ANTI-Rh 0 (D) BOUND TO RED CELLS | |
| US4210622A (en) | Kit for assay of immune complexes | |
| JPH02276969A (ja) | 肝炎の異なるマーカーの同時検出用試薬 | |
| SE446130B (sv) | Komposition for bestemning av human beta?712-mikroglobulin, forfarande for framstellning derav samt sett att bestemma human beta?712-mikroglobulin | |
| US4548909A (en) | Method of diagnosis | |
| US4141965A (en) | Assay of immune complexes | |
| GB1603406A (en) | Assay of immune complexes | |
| EP0806669B1 (de) | Verfahren zur Vorbereitung eines diagnostischen Reagenz für Hepatitis C Virusinfektion | |
| EP0313156B1 (de) | SnRNP-A-Antigen und Fragmente davon | |
| GB2030293A (en) | Composition for determination of human immunoglobulin G, process for its preparation and its use | |
| JP3558645B2 (ja) | 甲状腺自己免疫疾患の臨床診断薬としてのポリクローナルヒト抗−ｈＴｇ自己抗体の使用及び患者血清中での抗−ｈＴｇ自己抗体の検出用添加薬 | |
| JPS6340858A (ja) | 炎症の検出とその新しい抗体 | |
| CN111239403B (zh) | 一种β2微球蛋白胶乳增强免疫比浊试剂盒及应用 | |
| EP0106615B1 (de) | Test der freien Portion von Substanzen in biologischen Flüssigkeiten | |
| McCullough | Granulocyte antigen systems and antibodies and their clinical significance | |
| AU625344B2 (en) | Chlamydia half-sandwich immunoassay | |
| JPH0232258A (ja) | ヒトの体液中の抗体力価の測定法及びクラス特異性抗体の測定法 | |
| JP2001337092A (ja) | 免疫学的測定方法及び測定用試薬 | |
| GB2053469A (en) | Composition for determining human erythropoietin its preparation and use | |
| Ramos et al. | A latex particle assay for platelet‐associated IgG | |
| EP0485377A1 (de) | Festphase-immuno-testverfahren mit etikettierten konjugaten | |
| JP3216473B2 (ja) | 抗梅毒トレポネマ抗体の測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7907118-9 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7907118-9 Format of ref document f/p: F |